Achmea Investment Management B.V. Sells 29,356 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Achmea Investment Management B.V. lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 93.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,914 shares of the medical research company's stock after selling 29,356 shares during the quarter. Achmea Investment Management B.V.'s holdings in IQVIA were worth $376,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IQV. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of IQVIA by 789.9% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 227,512 shares of the medical research company's stock worth $44,708,000 after purchasing an additional 201,945 shares during the period. EverSource Wealth Advisors LLC increased its position in IQVIA by 9.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,482 shares of the medical research company's stock worth $291,000 after buying an additional 131 shares during the last quarter. Sequoia Financial Advisors LLC raised its stake in shares of IQVIA by 13.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 85,299 shares of the medical research company's stock valued at $16,762,000 after buying an additional 10,245 shares during the period. PFG Advisors grew its stake in shares of IQVIA by 45.3% during the 4th quarter. PFG Advisors now owns 6,068 shares of the medical research company's stock worth $1,192,000 after acquiring an additional 1,893 shares during the period. Finally, Inspire Advisors LLC raised its stake in IQVIA by 10.1% in the 4th quarter. Inspire Advisors LLC now owns 2,584 shares of the medical research company's stock valued at $508,000 after acquiring an additional 236 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

IQVIA Trading Down 0.9 %

IQV traded down $1.75 during midday trading on Wednesday, reaching $186.80. 1,008,388 shares of the company's stock traded hands, compared to its average volume of 1,227,564. The stock has a market capitalization of $32.93 billion, a price-to-earnings ratio of 24.91, a P/E/G ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 52 week low of $179.28 and a 52 week high of $256.34. The firm has a fifty day moving average of $196.06 and a two-hundred day moving average of $209.52. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Bank of America dropped their price target on IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a research report on Friday, December 13th. Leerink Partners reissued an "outperform" rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, Barclays cut their target price on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.